echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > China's self-developed ADC new drug approved for marketing for gastric cancer treatment

    China's self-developed ADC new drug approved for marketing for gastric cancer treatment

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The reporter learned from the Management Committee of Yantai Development Zone on the 10th that China's first original antibody-conjugated drug (ADC) new drug-vedicitumumab, declared by Rongchang Biopharmaceutical (Yantai) Co.
    , Ltd.
    , was approved by the China Food and Drug Administration Listing approval
    .


    Stomach cancer is the second largest cancer in China, with approximately 470,000 new patients in 2020


    The reporter learned from the Management Committee of Yantai Development Zone on the 10th that China's first original antibody-conjugated drug (ADC) new drug-vedicitumumab, declared by Rongchang Biopharmaceutical (Yantai) Co.


    , Ltd.
    , was approved by the China Food and Drug Administration Listing approval


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.